Sartorius, Stedim Biotech shares rise on 'positive' mid-term guidance

Sartorius AG

17/03/2026 08:43

** Shares of Sartorius Stedim Biotech STDM.PA rise 4.5%, while those in its German parent Sartorius SATG.DE gain 3.3%, after the pharma group set new mid-term growth targets

** The French unit, Stedim Biotech, eyes organic sales revenue growth of 9% to 12% from 2027, while the parent eyes growth of 8% to 11%

** "The new mid-term guidance, in particular for Stedim, looks positive when compared with consensus or peers," Oddo BHF analyst Olivier Metzger says

** J.P. Morgan says shares in Sartorius and its French unit have underperformed since the companies reported FY results in February, due to concerns over the mid-term guidance

** If gains hold, Stedim Biotech shares are on track for their best day since mid-October

** Stedim Biotech shares top the pan-European STOXX 600 .STOXX

(Reporting by Lucie Barbier and Emanuele Berro)

((Email: lucie.barbier@thomsonreuters.com))